A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | MicrobiomeTrials← Back to trialsNCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-05-06Est. Completion: 2026-12-01
Enrollment target: 100 participants Locations- TG Therapeutics Investigational Trial Site, La Jolla, California, United States
- TG Therapeutics Investigational Trial Site, Ann Arbor, Michigan, United States
- TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States
- TG Therapeutics Investigational Trial Site, New York, New York, United States
- TG Therapeutics Investigational Trial Site, Rochester, New York, United States
- TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
- TG Therapeutics Investigational Trial Site, Columbus, Ohio, United States
- TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Type 1 Diabetes
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta…
Birmingham, United StatesEst. completion Oct 11, 2027
Chronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple Sclerosis
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the stu…
Newport Beach, United StatesEst. completion Jun 2029